Curated News
By: NewsRamp Editorial Staff
October 14, 2025
NeuroOne Expands Global Patent Portfolio for Neurological Treatments
TLDR
- NeuroOne's expanded patent portfolio provides competitive advantages in neurological device markets with exclusive rights to temperature-sensing electrodes and spinal stimulation technologies.
- NeuroOne secured patents through USPTO and European Patent Office processes covering electrode temperature sensors, spinal cord stimulation arrays, and manufacturing methods for neural probes.
- These patented technologies improve neurological disorder treatments by enabling safer brain ablations for seizures and less invasive spinal pain relief without surgical incisions.
- NeuroOne now holds its first European patent for a paddle electrode that treats back pain percutaneously, avoiding traditional surgery through innovative thin-film technology.
Impact - Why it Matters
This development matters because it represents significant advancement in neurological treatment options that could directly impact millions of patients suffering from conditions like epilepsy, Parkinson's disease, and chronic pain. The patented technologies enable less invasive procedures with enhanced safety features, potentially reducing surgical risks, recovery times, and healthcare costs. For patients with drug-resistant epilepsy, the temperature-controlled ablation system offers new hope for seizure control without traditional brain surgery risks. The spinal cord stimulation technology could revolutionize pain management for failed back surgery patients, providing relief without major surgical incisions. These innovations address critical gaps in neurological care where current treatments often involve significant side effects or limited effectiveness, potentially improving quality of life for patients worldwide while advancing the field of neuromodulation therapy.
Summary
NeuroOne Medical Technologies Corporation (Nasdaq: NMTC), a pioneering medical technology company focused on neurological disorders, has significantly strengthened its intellectual property position with three major patent developments across international markets. The company announced a Notice of Allowance from the United States Patent and Trademark Office for U.S. Patent Application 17/860,232 covering "Probe Devices with Temperature Sensors and Related Systems and Methods," which represents crucial safety technology for brain ablation procedures. Additionally, NeuroOne secured its first European patent (EP 4013481) for "Spinal Cord Stimulation Systems, Methods, and Devices" featuring a deployable electrode array body, and received U.S. Patent 12,435,407 covering manufacturing methods for neural probe and spinal cord stimulation devices.
According to CEO Dave Rosa, these patent achievements represent significant milestones in NeuroOne's strategy to expand its technology platform across broader applications and use cases. The temperature control technology covered by the U.S. patent allowance is described as "an integral feature" of the company's OneRF Ablation System®, providing critical safety measures for patients undergoing brain ablations to treat seizures. The European patent specifically addresses spinal cord stimulation with a percutaneously placed paddle electrode designed to eliminate the need for surgical incisions in treating lower back pain. These developments build upon NeuroOne's existing robust portfolio, which includes four additional issued U.S. patents, seven pending U.S. applications, and eight pending foreign applications covering various thin-film electrode technologies optimized for functionality and minimal profile.
The company's growing intellectual property foundation supports its mission to develop minimally invasive, high-definition solutions for EEG recording, monitoring, ablation, drug delivery, and stimulation for patients suffering from epilepsy, Parkinson's disease, dystonia, essential tremors, chronic pain, and other neurological disorders. NeuroOne's technology platform aims to improve patient outcomes while reducing procedural costs, with potential future applications in depression, mood disorders, pain management, incontinence, high blood pressure, and artificial intelligence. For more information about the company's innovative approaches to neurological care, visit their website at nmtc1.com, where investors and interested parties can learn more about their groundbreaking work in medical technology.
Source Statement
This curated news summary relied on content disributed by NewMediaWire. Read the original source here, NeuroOne Expands Global Patent Portfolio for Neurological Treatments
